Showing results (171-180 of 212) with videos related to
Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With <i>RAS/BRAF</i> Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II TrialKanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan, et al.Clinical and Translational Radiation Oncology|January 31, 2022
NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experienceAlexander F Bagley, Ethan B Ludmir, Anirban Maitra, et al.Advanced Biology|March 28, 2022
Understanding Suboptimal Response to Immune Checkpoint InhibitorsMojun Zhu, Henan Zhang, Katrina S Pedersen, et al.NPJ Precision Oncology|February 13, 2023
Survival improvement for patients with metastatic colorectal cancer over twenty yearsFadl A Zeineddine, Mohammad A Zeineddine, Abdelrahman Yousef, et al.Cancer Research Communications|December 12, 2023
Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment TerminationKristen Simmons, Jane V Thomas, Kaysia Ludford, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 13, 2016
Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or MortalityJason W Denbo, Morgan L Bruno, Jordan M Cloyd, et al.Nature Communications|October 6, 2025
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancerMing Lei, Michael J Overman, Jin Yao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2021
Clinical and Functional Characterization of Atypical <i>KRAS</i>/<i>NRAS</i> Mutations in Metastatic Colorectal CancerJonathan M Loree, Yucai Wang, Muddassir A Syed, et al.Journal for Immunotherapy of Cancer|August 25, 2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)Benny Johnson, Cara L Haymaker, Edwin R Parra, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2017
4-1BB Agonist Focuses CD8<sup>+</sup> Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic CancerDonastas Sakellariou-Thompson, Marie-Andrée Forget, Caitlin Creasy, et al.Pageof 22